RxDoctor Payments DataLook up a doctor →

Curtis Dunshee, MD

Urology · Tucson, AZNPI 1538161880

Payments from drug & device makers

$15,981,112in general payments, 2019–2025

Across 1,575 payments — averaging $10,147 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$10.4M
  • Medivation LLC.$3.6M
  • Janssen Research & Development, LLC$896K
  • AstraZeneca$320K
  • Siemens Medical Solutions USA, Inc.$176K
  • Astellas Pharma Global Development$157K
  • plus $349K from 41 others
$85,672in research payments, 2019–2025

Across 78 payments — averaging $1098.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$68K
  • Dendreon Pharmaceuticals LLC$10K
  • Astellas Pharma Global Development$8K

What the payments were for

  • Consulting fees$22,53849%
  • Speaking & faculty fees$10,85923%
  • Travel & lodging$3,3837%
  • Food & beverage$9,16020%
  • Education$4831%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,981,112 in reported general payments places this provider in the 95th percentile of 269 urology providers in Arizona.

See all urology providers in Arizona

Medicare billing

Part B allowed, 2024
$304,896
Medicare patients
470
Services billed
15,810

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide43$603,585
NubeqaDarolutamide23$307,966
Abiraterone Acetate130$241,169
OrgovyxRelugolix79$205,672
ZytigaAbiraterone Acetate15$167,750
MyrbetriqMirabegron41$31,396
ElmironPentosan Polysulfate Sodium12$11,838
Testosterone32$6,168
Potassium Citrate ErPotassium Citrate32$4,780
Tamsulosin Hcl286$4,183
Finasteride205$2,489
Testosterone Cypionate31$1,287
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim37$742
Prednisone93$639
Dutasteride15$580

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$512$634,98184 claims
BayerNubeqa$4,417$307,96623 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$1,963$241,169130 claims
Sumitomo Pharma America, Inc.Orgovyx$152,165$205,67279 claims
Johnson & JohnsonZytiga$540$167,75015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 269 urology providers in Arizona.

Other urology in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →